<DOC>
	<DOC>NCT03033134</DOC>
	<brief_summary>The purpose of this study is to confirm the safety and effectiveness of the BSJ003W in Japanese patients with non-valvular atrial fibrillation at increased risk of thromboembolism in Japanese Clinical environment</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Effectiveness of the Left Atrial Appendage Closure Therapy Using BSJ003W</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1. The subject is Japanese, over 20 years old and provides written informed consent to participate in the trial 2. The subject has documented paroxysmal, persistent or permanent nonvalvular atrial fibrillation 3. The subject has a calculated CHA2DS2VASc score of 2 or greater and is recommended for longterm oral anticoagulation therapy 4. The subject is deemed by their physicians to be suitable for anticoagulant therapy and have an appropriate rationale to seek a nonpharmacologic alternative to warfarin 5. The subject is eligible to come off warfarin therapy if the LAA is sealed (i.e. the subject has no other conditions that would require warfarin therapy). 1. The subject has a prior stroke (ischemic or hemorrhagic) or transient ischemic attack within the 90 days prior to consent 2. The subject has had a myocardial infarction either nonST elevation or ST elevation myocardial infarction within 90 days prior to consent with or without intervention 3. The subject had or is planning to have any cardiac (e.g. cardioversion, coronary angiogram, percutaneous coronary intervention, cardiac ablation, etc.) or noncardiac invasive or surgical procedure (e.g. cataract surgery, endoscopy, etc.) within 30 days prior or 45 days after the BSJ003W implant 4. The subject has a history of atrial septal repair or has an atrial septal defect/persistent foramen ovale device 5. The subject has an implanted mechanical valve prosthesis in any position 6. The subject currently New York Heart Association class IV congestive heart failure 7. The subject is contraindicated to aspirin 8. The subject is contraindicated or seriously allergic to thienopyridine 9. The subject is of childbearing potential and is, or plans to become pregnant during the time of the study 10. The subject is not able and willing to return for required followup visits and examinations 11. Subjects who are currently enrolled in another investigational study (of which primary endpoint followup have not been completed yet). 12. The subject has other reason not to be eligible for this study per investigators' discretion.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>